免疫调节药物通过丢失Ikaros和Aiolos使骨髓瘤细胞对达雷妥尤单抗介导的细胞毒性致敏
该研究利用CRISPR-Cas9在人多发性骨髓瘤细胞系中敲除IKZF1/Ikaros和IKZF3/Aiolos,发现任一因子失活均重现免疫调节药物的细胞内在作用,导致细胞周期阻滞和凋亡,且转录变化与来那度胺处理高度重叠;Ikaros和Aiolos通过核小体重塑和去乙酰化酶复合物抑制包括CD38在内的干扰素刺激基因,其丢失激活干扰素样反应并上调CD38表面表达,使骨髓瘤细胞对达雷妥尤单抗诱导的NK细胞介导的抗体依赖性细胞毒作用致敏。
要点
- 敲除IKZF1/Ikaros或IKZF3/Aiolos可重现免疫调节药物的细胞内在作用,导致细胞周期阻滞和凋亡。
- Ikaros和Aiolos通过核小体重塑和去乙酰化酶复合物抑制CD38等干扰素刺激基因的表达。
- 免疫调节药物诱导Ikaros丢失或干扰素处理上调骨髓瘤细胞CD38表面表达,致敏达雷妥尤单抗的NK细胞介导抗体依赖性细胞毒作用。
核心结论
- 免疫调节药物通过丢失Ikaros和Aiolos激活干扰素样反应并上调CD38,使骨髓瘤细胞对达雷妥尤单抗介导的NK细胞抗体依赖性细胞毒作用致敏,为联合抗CD38单克隆抗体提供机制依据。
研究设计与样本
- 利用CRISPR-Cas9基因组编辑在人多发性骨髓瘤细胞系中敲除IKZF1/Ikaros和IKZF3/Aiolos,并进行转录变化评估。
主要发现
- 任一因子失活均重现免疫调节药物的细胞内在作用,导致细胞周期阻滞和凋亡。
- 因子丢失所致的转录变化与来那度胺处理高度重叠。
- 该作用不依赖IRF4-MYC轴下调,因细胞死亡时两者蛋白未一致性下调,且过表达任一因子未能挽救Ikaros丢失。
- Ikaros和Aiolos抑制包括CD38在内的干扰素刺激基因表达,其丢失激活干扰素样反应并促成骨髓瘤细胞死亡。
- 免疫调节药物诱导Ikaros丢失或干扰素处理上调骨髓瘤细胞CD38表面表达,致敏达雷妥尤单抗诱导的NK细胞介导抗体依赖性细胞毒作用。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Recent studies have demonstrated that the immunomodulatory drugs (IMiDs) lead to the degradation of the transcription factors Ikaros and Aiolos. However, why their loss subsequently leads to multiple myeloma (MM) cell death remains unclear. Using CRISPR-Cas9 genome editing, we have deleted IKZF1/Ikaros and IKZF3/Aiolos in human MM cell lines to gain further insight into their downstream gene regulatory networks. Inactivation of either factor alone recapitulates the cell intrinsic action of the IMiDs, resulting in cell cycle arrest and induction of apoptosis. Furthermore, evaluation of the transcriptional changes resulting from their loss demonstrates striking overlap with lenalidomide treatment. This was not dependent on reduction of the IRF4-MYC "axis," as neither protein was consistently downregulated, despite cell death occurring, and overexpression of either factor failed to rescue for Ikaros loss. Importantly, Ikaros and Aiolos repress the expression of interferon-stimulated genes (ISGs), including CD38, and their loss led to the activation of an interferon-like response, contributing to MM cell death. Ikaros/Aiolos repressed CD38 expression through interaction with the nucleosome remodeling and deacetylase complex in MM. IMiD-induced loss of Ikaros or treatment with interferon resulted in an upregulation of CD38 surface expression on MM cells, priming for daratumumab-induced NK cell-mediated antibody-dependent cellular cytotoxicity. These results give further insight into the mechanism of action of the IMiDs and provide mechanistic rationale for combination with anti-CD38 monoclonal antibodies.
引用
- Fedele PL, Willis SN, Liao Y, et al. IMiDs prime myeloma cells for daratumumab-mediated cytotoxicity through loss of Ikaros and Aiolos. Blood. 2018. PMID: 30228232. doi:10.1182/blood-2018-05-850727
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。